Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank
Publication date: November 2026 Source: Urologic Oncology: Seminars and Original Investigations, Volume 44, Issue 11 Author(s): Pavlos Msaouel, Salvatore La Rosa, Edwin Jason Abel, Laurence Albiges, Pedro C. Barata, Stephanie A. Berg, David A. Braun, James Brugarolas, Matthew T. Campbell, Marie I. Carlo, Katie Coleman, Nicholas G. Cost, Arighno Das, Arpita Desai, Nazli Dizman, Daniela Drago, Minas Economides, Daniel M. Geynisman, Meghan Griffith, Tasha Hall
Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. // Urologic Oncology: Seminars and Original Investigations. – URL: https://www.sciencedirect.com/science/article/pii/S1078143926007039?dgcid=rss_sd_all
Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urologic Oncology: Seminars and Original Investigations. https://www.sciencedirect.com/science/article/pii/S1078143926007039?dgcid=rss_sd_all
“Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.” Urologic Oncology: Seminars and Original Investigations.
@article{article117918,
title = {Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank},
journal = {Urologic Oncology: Seminars and Original Investigations},
url = {https://www.sciencedirect.com/science/article/pii/S1078143926007039?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment